drugset / Trial / NCT00477217

Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

NCT00477217

Phase 2 Withdrawn Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.

Timeline

Start
2008-01
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified

Indications